Webinar | Getting the best data from your cells: From tissue culture to final analysis
Sign Up to like & getrecommendations! Published in 2017 at "Science"
DOI: 10.1126/science.356.6336.446-b
Abstract: From tissue culture to final analysis, cell culture is a group of techniques used in the majority of life science laboratories. There are numerous standard methodologies, but many of the techniques used are continuously changing… read more here.
Keywords: webinar getting; tissue culture; final analysis; culture final ... See more keywords
Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor–Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis
Sign Up to like & getrecommendations! Published in 2023 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-22-1092
Abstract: Abstract Purpose: In PERTAIN's primary analysis (31 months’ median follow-up), adding pertuzumab to trastuzumab and an aromatase inhibitor (AI) with/without chemotherapy significantly improved progression-free survival (PFS) in patients with previously untreated HER2-positive and hormone receptor–positive… read more here.
Keywords: pertuzumab trastuzumab; final analysis; pertuzumab; analysis ... See more keywords
Abstract CT216: IMpower150 final analysis: Efficacy of atezolizumab (atezo) + bevacizumab (bev) and chemotherapy in first-line (1L) metastatic nonsquamous (nsq) non-small cell lung cancer (NSCLC) across key subgroups
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.am2020-ct216
Abstract: Background: The Ph III IMpower150 study (NCT02366143) showed PFS and OS benefit with atezo + bev + carboplatin (carbo) + paclitaxel (pac; ABCP; Arm B) vs bev + carbo + pac (BCP; Arm C) as… read more here.
Keywords: key subgroups; analysis; final analysis; bev ... See more keywords
Abstract GS1-03: Pyrotinib or placebo in combination with trastuzumab and docetaxel for untreated HER2-positive metastatic breast cancer (mBC): prespecified final analysis of progression-free survival (PFS) of the phase 3 PHILA trial
Sign Up to like & getrecommendations! Published in 2025 at "Clinical Cancer Research"
DOI: 10.1158/1557-3265.sabcs24-gs1-03
Abstract: Background: The interim analysis of the PHILA trial (NCT03863223) revealed that pyrotinib (an irreversible tyrosine kinase inhibitor targeting EGFR, HER2, and HER4) in combination with trastuzumab and docetaxel (PyroHT) significantly improved PFS compared to placebo… read more here.
Keywords: pfs; analysis; trial; group ... See more keywords
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma.
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2017-07-795047
Abstract: This FIRST trial final analysis examined survival outcomes in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM) treated with lenalidomide and low-dose dexamethasone until disease progression (Rd continuous), Rd for 72 weeks (18 cycles; Rd18),… read more here.
Keywords: survival outcomes; treatment; trial; final analysis ... See more keywords
Efficacy and Safety of Daratumumab in Intermediate/High-risk Smoldering Multiple Myeloma: Final Analysis of CENTAURUS.
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood.2024025897
Abstract: Early intervention of smoldering multiple myeloma (SMM) may delay progression to multiple myeloma. Here, we present the final analysis of the phase 2 CENTAURUS study (NCT02316106). In total, 123 patients with intermediate/high-risk SMM were randomized… read more here.
Keywords: multiple myeloma; intermediate high; high risk; final analysis ... See more keywords
Final Analysis of Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in the CANDOR Study.
Sign Up to like & getrecommendations! Published in 2023 at "Blood advances"
DOI: 10.1182/bloodadvances.2023010026
Abstract: CANDOR (NCT03158688) is a phase 3, randomized, open-label trial comparing carfilzomib, daratumumab, and dexamethasone (KdD) versus carfilzomib and dexamethasone (Kd) in adults with relapsed/refectory multiple myeloma (RRMM) with 1-3 prior therapies. The CANDOR study met… read more here.
Keywords: carfilzomib; carfilzomib dexamethasone; final analysis; candor ... See more keywords
Final analysis of phase III LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT).
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.7_suppl.141
Abstract: 141 Background: The first and second interim analyses (IA1 and IA2) of the LATITUDE study in NDx-HR mCNPC pts with addition of AA+P to ADT vs placebo (PBO)+ADT showed significant benefit in the coprimary endpoints… read more here.
Keywords: ndx mcnpc; analysis; final analysis; latitude study ... See more keywords
TIVO-3: Final OS analysis of a phase III, randomized, controlled, multicenter, open-label study to compare tivozanib to sorafenib in subjects with metastatic renal cell carcinoma (RCC).
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.5062
Abstract: 5062Background: Tivozanib (T) is a potent and highly selective VEGFR inhibitor. TIVO-3 is a phase 3 study designed to compare the efficacy and safety of T with those of sorafenib (S) as 3rd and 4th... read more here.
Keywords: analysis phase; phase; final analysis; study ... See more keywords
Tislelizumab (TIS; BGB-A317) plus chemotherapy (CT)/chemoradiotherapy (CRT) as positron emission tomography (PET)–guided neoadjuvant (n) treatment (tx) for resectable esophageal squamous cell carcinoma (R-ESCC): RATIONALE-213 final analysis.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.4027
Abstract: 4027 Background: Studies have shown overall survival improvements with nCRT + surgery vs surgery alone in locally advanced ESCC. However, preoperative CRT may have additional safety concerns, leading to some patients (pts) receiving nCT rather… read more here.
Keywords: surgery; rationale 213; crt; final analysis ... See more keywords